BICX · BioCorRx Inc. · Insider Trading
Substantial doubt about the company's ability to continue as a going concern.
“As of June 30, 2026, the Company had cash of $21,237 and working capital deficit of $8,231,326. During the six months ended June 30, 2026, the Company used net cash in operating activities of $873,260. The Company has incurred net losses since inception. These conditions raise substantial doubt about the Company's ability to continue as a going concern for the next twelve-month period since the date of the financial statements were issued.”View the 10-Q filed Aug 14, 2026
2 customers — 100% of revenue (three months ended June 30, 2026)
“The Company's revenues earned from sale of products and services for the three months ended June 30, 2026 included 100% from two customers of the Company's total revenues.”
2 customers — 99% of revenue (three months ended June 30, 2025)
“The Company's revenues earned from sale of products and services for the three months ended June 30, 2025 included 99% from two customers of the Company's total revenues.”
Trades by corporate insiders — officers, directors and holders of more than 10% of the shares — disclosed to the SEC on Forms 4 and 5. Form 3 supplies initial ownership rather than a trade; Form 4 must be filed within two business days of the trade.
| Date | Insider | Role | Type | Security | Shares |
|---|---|---|---|---|---|
| 2023-09-29 | Murthy Harsha |
Director |
Award↑
Filing footnotes — Common Stock, par value $0.001 (Direct)
These shares were issued to Mr. Murthy pursuant to a Director Agreement, dated January 20, 2023, by and between BioCorRx Inc. and Mr. Murthy. As compensation for his services, Mr. Murthy shall be issued, upon the last day of each fiscal quarter, provided Mr. Murthy is a member of the Board as of such date, the number of shares of the Company's common stock equivalent to $5,000 as determined based on the average closing price on the three trading days immediately preceding the last day of such quarter. The average closing price on the three trading days immediately preceding the date of this transaction was $1.75. |
Common Stock, par value $0.001
|
2,858 |
| 2023-09-29 | GALLIGAN JOSEPH J |
Director, 10% Owner |
Award↑
Filing footnotes — Common Stock, par value $0.001 (Direct)
These shares were issued to Mr. Galligan pursuant to a Director Agreement, dated February 16, 2021, by and between BioCorRx Inc. and Mr. Galligan. As compensation for his services, Mr. Galligan shall be issued, upon the last day of each fiscal quarter, provided Mr. Galligan is a member of the Board as of such date, the number of shares of the Company's common stock equivalent to $5,000 as determined based on the average closing price on the three trading days immediately preceding the last day of such quarter. The average closing price on the three trading days immediately preceding the date of this transaction was $1.75. |
Common Stock, par value $0.001
|
2,858 |
| 2023-09-29 | Felix Lourdes |
Director, CEO and CFO |
Award↑
Filing footnotes — Common Stock, par value $0.001 (Direct)
These shares were issued to Ms. Felix pursuant to a Director Agreement, dated March 1, 2019, by and between BioCorRx Inc. and Ms. Felix. As compensation for her services, Ms. Felix shall be issued, upon the last day of each fiscal quarter, provided Ms. Felix is a member of the Board as of such date, the number of shares of the Company's common stock equivalent to $5,000 as determined based on the average closing price on the three trading days immediately preceding the last day of such quarter. The average closing price on the three trading days immediately preceding the date of this transaction was $1.75. |
Common Stock, par value $0.001
|
2,858 |
| 2023-09-29 | Granier Brady James |
Director |
Award↑
Filing footnotes — Stock Option (Direct)
On September 29, 2023, the issuer granted the reporting person an option that was 100% vested on issuance. |
Stock Option
|
8,574 |
| 2023-09-29 | Ingargiola Luisa |
Director |
Award↑
Filing footnotes — Common Stock, par value $0.001 (Direct)
These shares were issued to Ms. Ingargiola pursuant to a Director Agreement, dated March 1, 2019, by and between BioCorRx Inc. and Ms. Ingargiola. As compensation for her services, Ms. Ingargiola shall be issued, upon the last day of each fiscal quarter, provided Ms. Ingargiola is a member of the Board as of such date, the number of shares of the Company's common stock equivalent to $5,000 as determined based on the average closing price on the three trading days immediately preceding the last day of such quarter. The average closing price on the three trading days immediately preceding the date of this transaction was $1.75. |
Common Stock, par value $0.001
|
2,858 |
| 2023-09-29 | Lucido Louis C. |
Director, President, 10% Owner |
Award↑
Filing footnotes — Common Stock, par value $0.001 (Direct)
These shares were issued to Mr. Lucido pursuant to a Director Agreement, dated March 1, 2019, by and between BioCorRx Inc. and Mr. Lucido. As compensation for his services, Mr. Lucido shall be issued, upon the last day of each fiscal quarter, provided Mr. Lucido is a member of the Board as of such date, the number of shares of the Company's common stock equivalent to $5,000 as determined based on the average closing price on the three trading days immediately preceding the last day of such quarter. The average closing price on the three trading days immediately preceding the date of this transaction was $1.75. |
Common Stock, par value $0.001
|
2,858 |
| 2021-03-31 | GALLIGAN JOSEPH J |
Director, 10% Owner |
Award↑
Filing footnotes — Common Stock, par value $0.001 (Direct)
These shares were issued to Mr. Galligan pursuant to a Director Agreement, dated February 16, 2021, by and between BioCorRx Inc. and Mr. Galligan. As compensation for his services, Mr. Galligan shall be issued, upon the last day of each fiscal quarter, provided Mr. Galligan is a member of the Board as of such date, the number of shares of the Company's common stock equivalent to $5,000 as determined based on the average closing price on the three trading days immediately preceding the last day of such quarter. The average closing price on the three trading days immediately preceding the date of this transaction was $2.16. |
Common Stock, par value $0.001
|
1,157 |